Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy

PloS One
Michael CollinsFranck Carbonnel

Abstract

Familial amyloid polyneuropathy (FAP) is a genetic disease leading to the production of a variant transthyretin (TTR) or a beta variant β2-microglobulin. FAP may be associated with refractory diarrhoea. In this study, we assessed the efficacy and tolerance of somatostatin analogues in refractory diarrhoea associated with FAP. FAP patients from the French national referral center who received somatostatin analogues for a refractory diarrhoea were retrospectively studied. We assessed remission of diarrhoea, as defined by a stool consistence of five or less on the Bristol stool scale, assessed after three to six months of follow-up. Stool frequency and continence before and after three to six months of treatment were also compared by the means of Wilcoxon and McNemar's exact tests, respectively. Fourteen patients treated with somatostatin analogues were evaluable. After three to six months of follow-up, 9/14 patients (64% 95%CI = [35%; 87%]) had remission of diarrhoea. This was significantly higher than a theoretical remission rate of 20% (p = 0.0004). There was a significant decrease of daily bowel movement from 6 to 2.5 per day (p = 0.002). Twelve/14 (85%) patients had incontinence at baseline vs 8/14 (57%) after three to six mo...Continue Reading

References

Nov 21, 1991·The New England Journal of Medicine·H C SoudahC Owyang
Jan 25, 1996·The New England Journal of Medicine·S W LambertsL J Hofland
Oct 19, 1999·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·N NyhlinO B Suhr
Dec 12, 2001·Alimentary Pharmacology & Therapeutics·A Szilagyi, I Shrier
Jun 7, 2007·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·George C NikouPetros P Sfikakis
Jun 15, 2012·The New England Journal of Medicine·Sophie ValleixVittorio Bellotti
Feb 22, 2013·Orphanet Journal of Rare Diseases·Yukio AndoFabrizio Salvi
Jun 26, 2013·Digestive Diseases·Ana Paula BarreirosGerd Otto
Aug 30, 2013·The New England Journal of Medicine·Teresa CoelhoOle B Suhr
Mar 26, 2014·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·S S Yarandi, S Srinivasan
Apr 29, 2014·Orphanet Journal of Rare Diseases·Jonas WixnerUNKNOWN THAOS investigators
Jul 12, 2014·The New England Journal of Medicine·Martyn E CaplinUNKNOWN CLARINET Investigators
Nov 28, 2015·Journal of the American College of Cardiology·Morie A GertzGiampaolo Merlini
Dec 15, 2015·Neurology and Therapy·Márcia Waddington Cruz, Merril D Benson
Jan 7, 2016·Current Opinion in Neurology·David AdamsUNKNOWN from the European Network for TTR-FAP (ATTReuNET)
Mar 16, 2017·Muscle & Nerve·Elie NaddafP James B Dyck

❮ Previous
Next ❯

Citations

Aug 28, 2019·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·Laura Obici, Ole B Suhr

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotide

Related Concepts

Related Feeds

Amyloidogenesis-associated Polyneuropathy

Amyloid deposits around nerves can damage and disrupt smooth information processing between the brain and organs. Here is the latest research on amyloidosis-associated polyneuropathies.

Adenomatous Polyposis Coli

Adenomatous polyposis coli is a protein encoded by the APC gene and acts as a tumor suppressor. Discover the latest research on adenomatous polyposis coli here.

Related Papers

AJR. American Journal of Roentgenology
Gianluca Di BellaMichele Gaeta
Medicina clínica
Pablo García-Pavíaen representación del Grupo de Estudio y Tratamiento de la Polineuropatía Amiloidótica Familiar por Transtiretina (GETPAF-TT
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
M InêsJ Costa
© 2022 Meta ULC. All rights reserved